Role of Emerging Risk Markers in Cardiometabolic Syndrome

Abstract

Cardiometabolic syndrome (CMS), also known as metabolic syndrome (MetS) is a common and silent epidemic, which is linked to type 2 diabetes mellitus, abdominal obesity, and a higher risk of cardiovascular disease. Comprehensive demographic, physiological, genetic, and clinical data were collected from 199 subjects suffering from varying degrees of Metabolic syndrome (MetS) and 100 healthy control subjects. Mutagen induced chromosome sensitivity analysis for DNA repair proficiency and the extent of somatic DNA damages by Cytokinesis-Block Micronuclei (CBMN) assay were also performed among the study subjects. The study found that individuals with CMS showed an elevated concentration of Lp-PLA2, MA and hsCRP. The study also showed an association between DNA damage and DNA repair among the test subjects. Microalbumin and Lp-PLA2 can be considered good markers for the early prediction of coronary artery disease (CAD) and several other cardiovascular diseases. In addition, the rising frequency of somatic DNA damage points to the varied degrees of MetS progression. Thus, novel biomarkers can identify patients who are at risk beyond traditional ones, thereby alleviating the possible CMS events and also other disorders related to CMS by following healthy lifestyle habits and proper medication.